Psychiatry & Neurology Doctors in Tamc, HI Accepting Medicare

3 Psychiatry & Neurology doctors found. Showing 1 - 3

Dr. Millard Dalton Brown Iii, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 1 Jarrett White Rd, Tamc, HI 96859 Phone: 808-433-5780

Dr. Wayne B Batzer, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 1 Jarrett White Rd, Schofield Barracks Health Clinic, Tamc, HI 96859 Phone: 808-433-8175    Fax: 808-433-8407

Dr. Raymond Scott Wilson, D.O. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 1 Jarrett White Rd, Tripler Army Medical Center Attn: Mchk-qs, Tamc, HI 96859 Phone: 808-626-1676

News Archive

Researchers discover certain proteins in osteoclasts that may be used to destroy cardiovascular calcification

​Cardiovascular calcification (deposits of minerals in heart valves and blood vessels) is a primary contributor to heart disease, the leading cause of death among both men and women in the United States according the Centers for Disease Control and Prevention (CDC).

FUJIFILM SonoSite donates point-of-care ultrasound to support relief efforts in Iraq

FUJIFILM SonoSite has donated a point-of-care ultrasound system to CADUS, an independent aid organisation supporting the relief effort in Iraq.

Researchers evaluate new drug for spinal muscular atrophy in a broader spectrum of patients

The rarity of spinal muscular atrophy (SMA) means that promising new treatments may be tested in only a limited spectrum of patients before approval. Investigators evaluated a newly approved drug, onasemnogene abeparvovec, in a broader spectrum of patients in order to obtain expanded data on its side effects profile.

MabCure closes private placement, converts bridge loan into equity securities

MabCure, Inc., a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, today announced that it has recently completed a private placement in the aggregate amount of $1 million. The amount is comprised of a $500,000 cash investment and the conversion of a $500,000 bridge loan that was made in September 2009, into equity securities.

ISCT announces reasons for opposing current version of REGROW Act on cell therapies

The International Society for Cellular Therapy, the global society of clinicians, researchers, regulatory specialists, technologists, and industry partners dedicated to the translation of cellular therapy into safe and effective therapies to improve patients' lives, today announces its reasons for opposition to the current version of the REGROW Act - the US government's legislative efforts to promote faster patient access to effective new cellular therapies.

Read more Medical News

› Verified 7 days ago